Larotrectinib CAS 1223403-58-4

Khoom Qhia:

Khoom npe: larotrectinib CAS TSIS: 1223403-58-4

Txhais:

LOXO-101;

Larotrectinib free puag;

(S) -N- (5 - ((R) -2- (2,5-difluorophenyl) pyrrolidin-1-yl) -pyrazolo [1,5-a] pyrimidin-3-yl) -3-hydroxypyrrolidine-1 -carboxamide;

Tshuaj& Cov Khoom Uas Lub Cev:

Zog: Dawb kom daj khoom

Ntsuas: ≥99.0%

Qhov ceev: 1.55 ± 0.1 g / cm3 (Pom zoo)

Performance Index Pheej Yeem: 1.725

Cia Li Cas: -20 ℃

Kev Solubility: DMSO: ≥ 4.6 mg / mL (10.74 mM)

Cov Ntaub Ntawv Kev Nyab Xeeb:

Kos Npe: Lo Lus Ceeb Toom

Cov Nqe Lus Ceeb Toom: H315 / 319/335

Cov ntawv ceeb toom ua ntej: P261 / P305+351+338 / P302+352

Larotrectinib (VITRAKVIR) yog qhov ncauj noj, me me molecule, cov xaiv tau zoo, tropomyosin receptor kinase (TRK) inhibitor uas tau tsim los ntawm Loxo Oncology hauv kev koom tes nrog Bayer AG ua kev kho mob rau cov neeg laus thiab cov menyuam yaus cov neeg mob qog nqaij hlav muaj mob neurotrophic receptor tyrosine kinase ( NTRK) noob fusions.

Larotrectinib yog qhov xaiv heev, muaj zog inhibitor ntawm TRKA, TRKB thiab TRKC (hauv vitro 50% inhibitory tas mus li 5–11 nmol / L), muaj tsawg heev lossis tsis muaj kev ua haujlwm tiv thaiv lwm cov kinase thiab tsis-kinase phiaj xwm [1, 2]. Kev txwv ntawm TRK tiv thaiv TRK kev ua haujlwm, ua rau ob leeg nkag mus ntawm lub cev ua haujlwm ntawm lub cev thiab ua rau txoj kev loj hlob ntawm cov qog nqaij hlav hauv cov qog uas overexpress TRKs.

Yog tias koj txaus siab rau peb cov khoom lossis muaj lus nug, thov koj xav tiv tauj peb!

Cov khoom lag luam hauv qab patent yog muab rau R& D lub hom phiaj nkaus xwb. Txawm li cas los xij, lub luag haujlwm kawg tau txiav txim siab nrog cov neeg yuav khoom.

Cim npe nrov: larotrectinib cas 1223403-58-4, tuam ntxhab, lwm tus neeg, Hoobkas, yuav, hauv Tshuag

• Tug: Imeglimin CAS 775351-65-0
• Tom ntej: Ruxolitinib CAS 941678-49-5